

ALEMBIC LIMITED
CIN:126100GJ1907PLC000033
Regd.Office: Alembic Road, Vadodara 390 003
Ph:0265 6637000
www.alembiclimited.com Email:alembic.investors@alembic.co.in

### Statement of Consolidated Unaudited Financial Results for the Quarter and Half year ended 30th September, 2024

Rs. in Lakhs

							Rs. in Lakhs
		Quarter Ended			Half Yea	Year Ended	
Sr.		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
No	Particulars	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	5,291	5,078	3,228	10,370	6,912	15,749
2	Other Income	6,560	196	4,787	6,756	5,051	5,477
3	Total Income	11,852	5,274	8,015	17,126	11,963	21,226
4	Expenses						
	Cost of Materials Consumed	141	286	246	427	380	862
	Cost of Construction	1,659	1,191	796	2,849	1,718	3,981
	Changes in Inventories of Finished Goods and WIP	71	131	(58)	202	189	53
	Employee Benefit Expenses	652	773	563	1,425	1,190	2,303
	Finance Costs	67	49	13	116	27	111
	Depreciation and amortisation expense	268	250	186	518	370	784
	Other Expenses	810	657	665	1,466	1,331	2,864
	Total Expenses	3,669	3,337	2,412	7,006	5,205	10,957
5	Profit Before Tax (3-4)	8,183	1,937	5,603	10,120	6,758	10,269
3	From Berore rax (5-4)	8,183	1,557	3,003	10,120	0,738	10,203
6	Tax Expenses						
	Current Tax	916	234	534	1,150	647	1,002
	Deferred Tax	(465)	(38)	196	(503)	242	482
	Short / (Excess) Provision of earlier years	(0)	-	(297)	(0)	(297)	(502
7	Net Profit after tax for the Period	7,731	1,742	5,171	9,474	6,166	9,287
8	Share of Associate's Profit/(Loss)	4,371	3,840	3,897	8,210	7,339	17,575
9	Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)	12,102	5,582	9,068	17,684	13,506	26,862
10	Other Comprehensive Income						
10	A (i) Items that will not be reclassified to Profit or (Loss)  (ii) Income tax relating to items that will not be reclassified to Profit	(2,794)	4,348	(3,174)	1,554	830	(6,855)
	or (Loss)	(355)	(490)	367	(845)	(86)	775
	B (i) Items that will be reclassified to Profit or (Loss)	31	(3)	74	28	49	108
11	Total Comprehensive Income/(Loss) for the Period	8,984	9,436	6,334	18,420	14,299	20,890
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)						1,85,911
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	4.71	2.17	3.53	6.89	5.26	10.46





Rs. in Lakhs Segment wise Consolidated Revenue and Results Half Year Ended Year Ended Quarter Ended 30.09.2024 30.06.2024 30.09.2023 30.09.2024 30.09.2023 31.03.2024 Sr. (Audited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) No **Particulars** 1 Segment Revenue Revenue from Operations 1,072 1.729 3,174 785 1.818 a. Active Pharmaceutical Ingredients Business 746 12,574 4,546 4,006 2,442 8,552 5,183 b. Real Estate Business 10,370 6,912 15,749 **Total Income from Operations (Net)** 5,291 5,078 3,228 Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment) 137 336 a. Active Pharmaceutical Ingredients Business 36 50 92 86 1,786 1,924 849 3,710 1,825 5,126 b. Real Estate Business 1,822 1,974 940 3,796 1,962 5,462 Total Unallocable Income and Expenditure (116) (27)(111)(i) Interest Expense (67)(49)(13)(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset 6,398 31 4,651 6,430 4,775 4,869 (iii) Other Income / (Expense) 11 47 49 30 (20)25 10,120 6,758 10,269 5,603 **Total Profit Before Tax** 8,183 1,937 Segment Assets a. Active Pharmaceutical Ingredients Business 18,215 18,752 18,414 18,215 18,414 18,380 41,848 33,628 41,848 33,628 36,700 b. Real Estate Business 39,663 1,84,033 1,86,495 1,74,931 1,84,033 1,74,931 1,77,798 c. Unallocated 2,32,877 Total 2,44,096 2,44,910 2,26,972 2,44,096 2,26,972 Segment Liabilities 3,291 3,582 2,943 3,291 2,943 2,941 a. Active Pharmaceutical Ingredients Business 8,987 8,252 12,116 8,252 7,682 12,116 b. Real Estate Business

# Total

c. Unallocated

- 1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- 2 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara

Date: 8th November, 2024

VADDARA \*

Wadodara Co

4.046

19,453

4.349

16,918

3.811

15,006

huf

4.046

19,453

For Alembic Limited

3,811

15,006

3,698

14,321

Statement of Consolidated Assets and Liabilities		Rs. in Lakhs	
	As at 30th	As at 31st	
Particulars	September, 2024	March, 2024	
	(Unaudited)	(Audited)	
ASSETS			
Non-Current Assets			
	13,115	13,054	
(a) Property, Plant and Equipments	22	110	
(b) Capital Work-in-Progress	25,388	23,818	
(c) Investment Property		23,616	
(d) Goodwill	5	•	
(e) Financial Assets			
(i) Investments	32,890	31,303	
(ii) Investments accounted using Equity Method	1,48,143	1,46,162	
(iii) Others	1,060	1,186	
(f) Other Non-Current Assets	3,500	3,500	
	2,24,124	2,19,138	
Current Assets			
(a) Inventories	9,705	9,260	
(b) Financial Assets			
(i) Investments	3,943	1,134	
(ii) Trade Receivables	4,346	1,976	
	175	126	
(iii) Cash and Cash Equivalents	159	120	
(iv) Bank Balances other than Cash and Cash Equivalents	보면 얼마나가 있었다.		
(v) Others	299	267	
(c) Other Current Assets	1,345	856	
	19,972	13,739	
TOTAL - ASSETS	2,44,096	2,32,877	
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share Capital	5,136	5,136	
(b) Other Equity	2,19,507	2,13,421	
, , , , , , , , , , , , , , , , , , , ,	2,24,643	2,18,556	
Liabilities			
Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	1,263	739	
(ii) Other Financial Liabilities	1,247	1,140	
(b) Provisions	252	191	
(c) Deferred Tax Liability (Net)	3,579	3,219	
(c) Deferred Tax Clability (Net)	6,340	5,289	
Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	358	176	
(ii) Trade Payables			
a) total outstanding dues of Micro and Small Enterprises	498	650	
b) total outstanding dues of Others	2,694	2,44	
(iii) Other Financial Liabilities	806	640	
(b) Other Current Liabilities	6,121	2,49	
	2,169	2,14:	
(c) Provisions	467	47	
(d) Current Tax Liabilities (Net)	13,112	9,03	
	2.44.000	2 22 07	
TOTAL - EQUITY AND LIABILITIES	2,44,096	2,32,87	

For Alembic Limited

Place : Vadodara

Date: 8th November, 2024



Wadodara D

### **Alembic Limited**

### Consolidated Statement of Cash Flow for Half Year ended 30th September, 2024

Rs. In Lakhs

		Rs. In Lakhs
	For the Half Year	For the Half Year
<b>A.</b> 17. 17.	Ended on 30th	Ended on 30th
Particulars	September, 2024	September, 2023
	(Unaudited)	(Unaudited)
CASH FLOW FROM OPERATING ACTIVITIES:		
Net Profit before tax	10,120	6,758
Add:		
Depreciation	518	370
Interest charged	116	27
(Gain) / Loss on sale of Property, Plant and Equipments	(0)	(16)
Other Non cash items	(157)	(187)
Less:		
Interest Income	(100)	(39)
	(6,295)	(4,591)
Dividend Income	4,204	2,321
Operating Profit before change in working capital	4,204	Z,JZI
Working capital changes:		
Add / (Less):	(445)	208
(Increase) / Decrease in Inventories	(445)	
(Increase) / Decrease in Trade Receivables	(2,370)	193
(Increase) / Decrease in Other Assets	(489)	(4,524)
(Increase) / Decrease in Financial Assets	94	(292)
Increase / (Decrease) in Trade Payables	89	1,247
Increase / (Decrease) in Financial Liabilities	235	66
Increase / (Decrease) in Other Liabilities	3,626	109
Increase / (Decrease) in Provisions	76	52
Cash generated from operations	5,020	(621)
보기에 하게 그렇게 되었다면 하게 하게 하면 하게 되었다면 하는데 얼마나 하는데 얼마나 하는데 하는데 하는데 보고 있는데 그는데 하는데 하는데 하는데 하는데 하는데 하는데 하는데 하는데 하는데 하		
Add / (Less):	(1,162)	(452)
Direct taxes paid (Net of refunds)	3,857	(1,073)
Net cash inflow from operating activities (A)	3,037	(1,073)
CASH FLOW FROM INVESTING ACTIVITIES:		
Add:		
Proceeds from sale of Property, Plant and Equipments	0	18
Proceeds from sale / redemption of Investments	8,354	11,363
Interest received	100	39
Dividend received	6,295	4,591
Less:	14,749	16,010
2000		
Purchase of PPE and Investment Property/increase in CWIP and Capital Advances	2,063	2,701
Purchase of Investments	10,921	6,966
Increase in Restricted Bank Balances other than Cash & Cash Equivalents	38	32
increase in Restricted Bank Balances other than Cash & Cash Equivalents	13,022	9,699
and the first the state (D)	1,727	6,312
Net cash inflow from Investing activities (B)	2,72,	5/5
C CASH FLOW FROM FINANCING ACTIVITIES:		
Add:		F00
Proceeds from long term borrowings	706	500
Less:		
Dividends paid	6,124	
Interest and other finance costs	116	27
	6,241	5,644
	/F F2F	/ / 144
Net cash inflow from Financing activities ( C)	(5,535	) (5,144
I. Net (Decrease) / Increase in cash and cash equivalents (A+B+C)	49	95
II. Cash and cash equivalents at the beginning of the period	126	93
	175	
III. Cash and cash equivalents at the end of the period (I+II)	1/3	100
IV. Cash and cash equivalents at the end of the period	477	187
Balances with Bank	174	
Cash on Hand	1	
Cash and cash equivalents	175	188

For Alembic Limited

Place : Vadodara Date : 8th November, 2024





ALEMBIC LIMITED
CIN:L26100GJ1907PLC000033
Regd.Office: Alembic Road, Vadodara 390 003
Ph:0265 6637000
www.alembiclimited.com Email:alembic.investors@alembic.co.in

### Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended 30th September, 2024

Rs. in Lakhs

					11-161/	u Ended	Rs. in Lakhs
			Quarter Ended		Half Yea		Year Ended
Sr.		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
No.	Particulars	(Unaudited)	(Unaudited)	(Unudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	5,110	4,908	3,115	10,018	6,680	15,225
2	Other Income	6,559	189	4,786	6,748	5,045	5,462
3	Total Income	11,669	5,097	7,901	16,766	11,725	20,687
4	Expenses	141	286	246	427	380	862
	Cost of Materials Consumed			796	2,849	1,718	3,981
	Cost of Construction	1,659	1,191 131	(58)	202	189	53
	Changes in Inventories of Finished Goods and WIP	71	773	563	1,425	1,190	2,303
	Employee Benefit Expenses	652 51	34	5	85	10	69
	Finance Costs		241	177	499	351	746
	Depreciation and amortisation expense	259 749	582	606	1,331	1,229	2,402
	Other Expenses	/43	302	000	2,002	_,	
	Total Expenses	3,582	3,238	2,334	6,820	5,067	10,415
5	Profit Before Tax (3-4)	8,087	1,859	5,566	9,946	6,658	10,272
6	Tax Expenses Current Tax Deferred Tax	892 (465)	213 (37)	525 196	1,105 (502)		1,000 484
	Short / (Excess) Provision of earlier years	(0)	-	(297)	(0)		(501
7	Net Profit after tax for the Period	7,660	1,684	5,143	9,343	6,092	9,289
8	Other Comprehensive Income  (i) Items that will not be reclassified to Profit or (Loss)	(2,801)	4,459	(3,117)	1,658	890	(6,409
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(354)	(510)	367	(863)	(86)	747
9	Total Comprehensive Income/(Loss) for the Period	4,505	5,633	2,394	10,137	6,896	3,627
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)						48,233
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	2.98	0.66	2.00	3.64	2.37	3.62





**Alembic Limited** 

Sr.		Quarter Ended			Half Yea	Year Ended	
No.	Particulars	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment Revenue						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	746	1,072	785	1,818	1,729	3,174
	b. Real Estate Business	4,364	3,835	2,330	8,200	4,951	12,051
	Total Income from Operations (Net)	5,110	4,908	3,115	10,018	6,680	15,225
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each						
	segment)						
	a. Active Pharmaceutical Ingredients Business	36	50	92	86	137	336
	b. Real Estate Business	1,674	1,831	804	3,505	1,708	5,087
	Total	1,710	1,881	895	3,591	1,845	5,423
	Unallocable Income and Expenditure						
	(i) Interest Expense	(51)	(34)	(5)	(85)	(10)	(69
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	6,398	31	4,651	6,430	4,775	4,869
	(iii) Other Income / (Expense)	30	(20)	25	11	47	49
	Total Profit Before Tax	8,087	1,859	5,566	9,946	6,658	10,272
3	Segment Assets						
	a. Active Pharmaceutical Ingredients Business	18,215	18,752	18,414	18,215	18,414	18,380
	b. Real Estate Business	40,917	38,784	32,819	40,917	32,819	35,897
	c. Unallocated	44,564	45,057	47,323	44,564	47,323	40,310
	Total	1,03,697	1,02,592	98,556	1,03,697	98,556	94,587
4	Segment Liabilities						
	a. Active Pharmaceutical Ingredients Business	3,291	3,582	2,943	3,291	2,943	2,941
	b. Real Estate Business	11,264	8,154	7,659	11,264	7,659	6,941
	c. Unallocated	4,291	4,347	3,808	4,291	3,808	3,829
	Total	18,846	16,084	14,410	18,846	14,410	13,711

#### Notes:

- 1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- 2 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

Place : Vadodara

Date: 8th November, 2024

VADODARA \*\*

Vadodara D

Statement of Standalone Assets and Liabilities		Rs. in Lakhs	
	As at 30th	As at 31st	
Particulars	September, 2024	March, 2024	
	(Unaudited)	(Audited)	
ASSETS			
Non-Current Assets			
(a) Property, Plant and Equipments	13,115	13,054	
(b) Capital Work-in-Progress	22	110	
(c) Investment Property	25,119	23,529	
(d) Financial Assets			
(i) Investments	41,564	39,978	
(ii) Others	938	1,064	
(e) Other Non-Current Assets	3,500	3,500	
(-)	84,259	81,235	
Current Assets			
(a) Inventories	9,705	9,260	
(b) Financial Assets			
(i) Investments	3,755	1,086	
(ii) Trade Receivables	4,110	1,740	
(iii) Cash and Cash Equivalents	131	99	
(iv) Bank Balances other than Cash and Cash Equivalents	159	120	
(v) Others	299	267	
(c) Other Current Assets	1,279	780	
(c) other carrent research	19,438	13,352	
TOTAL - ASSETS	1,03,697	94,587	
EQUITY AND LIABILITIES			
Equity	5,136	5,136	
(a) Equity Share Capital	79,715	75,740	
(b) Other Equity	84,851	80,876	
Liabilities			
Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	1,263	739	
(ii) Other Financial Liabilities	704	646	
(b) Provisions	252	191	
(c) Deferred Tax Liability (Net)	3,578 5,796	3,217 4,793	
Current Liabilities	3,796	4,733	
(a) Financial Liabilities			
(i) Borrowings	358	176	
(ii) Trade Payables			
a) total outstanding dues of Micro and Small Enterprises	474	652	
b) total outstanding dues of Others	2,649	2,389	
(iii) Other Financial Liabilities	670	535	
(b) Other Current Liabilities	6,016	2,413	
(c) Provisions	2,169	2,143	
(d) Current Tax Liabilities (Net)	713	612	
V. J	13,050	8,918	
TOTAL - EQUITY AND LIABILITIES	1,03,697	94,587	

For Alembic Limited

Place : Vadodara

Date: 8th November, 2024

VADODARA \*

Vadodara D

### Standalone Statement of Cash Flow for Half Year ended 30th September, 2024

Rs. in Lakhs

		For the Half Year	For the Half Year
		Ended on 30th	Ended on 30th
	Particulars		
		September, 2024 (Unaudited)	(Unaudited)
		(Unaudited)	(Offaudited)
	FLOW FROM OPERATING ACTIVITIES:	0.045	6.650
Net P	Profit before tax	9,946	6,658
Add:		***	254
	Depreciation	499	351
	Interest charged	85	10
	(Gain) / Loss on sale of Property, Plant and Equipments	(0)	(16)
	Other Non cash items	(154)	(184)
Less:			
	Interest Income	(100)	(38)
	Dividend Income	(6,295)	(4,591
Oper	ating Profit before change in working capital	3,982	2,189
Work	king capital changes:		
	/ (Less) :		
	(Increase) / Decrease in Inventories	(445)	208
	(Increase) / Decrease in Trade Receivables	(2,370)	260
	(Increase) / Decrease in Other Assets	(499)	(4,497
	(Increase) / Decrease in Financial Assets	94	(292
	Increase / (Decrease) in Trade Payables	82	1,203
	Increase / (Decrease) in Financial Liabilities	154	269
	Increase / (Decrease) in Other Liabilities	3,603	92
		76	52
	Increase / (Decrease) in Provisions	4,676	(517
	generated from operations	4,070	(52.
	/ (Less):	(1,004)	(395
	et taxes paid (Net of refunds)	3,672	(912
Net	cash inflow from operating activities (A)	3,072	(522)
CASH	H FLOW FROM INVESTING ACTIVITIES:		
Add:			
	Proceeds from sale of Property, Plant and Equipments	0	18
	Proceeds from sale / redemption of Investments	8,351	11,046
	Interest received	100	38
		6,295	4,591
	Dividend received	14,746	15,692
Less:			
	Durch and FDDE and Investment Property/increase in CWIR and Canital Advances	2,063	2,684
	Purchase of PPE and Investment Property/increase in CWIP and Capital Advances	10,781	
	Purchase of Investments	38	32
	Increase in Restricted Bank Balances other than Cash & Cash Equivalents	12,882	
		1,864	6,090
	cash inflow from Investing activities (B)	1,804	1 0,050
CASH	H FLOW FROM FINANCING ACTIVITIES:		
Add:			
	Proceeds from long term borrowings	706	500
Less			
	Dividends paid	6,124	
	Interest and other finance costs	85	
		6,210	5,62
		/F F04	\ /E 127
Net	cash inflow from Financing activities (C)	(5,504	) (5,127
		32	52
. Net	(Decrease) / Increase in cash and cash equivalents (A+B+C)	32	]
II. Cash	n and cash equivalents at the beginning of the period	99	8:
	n and cash equivalents at the end of the period (I+II)	131	. 13
5431			
IV. Cash	n and cash equivalents at the end of the period		
Bala	inces with Bank	130	13
	n on Hand	1	
	n and cash equivalents	131	13!

For Alembic Limited

Place : Vadodara

Date: 8th November, 2024





# CNK & Associates LLP Chartered Accountants

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Alembic Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> September, 2024 and year to date from 1<sup>st</sup> April, 2024 to 30<sup>th</sup> September, 2024 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

## 4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Consolidated Financial Statements for the year ended 31st March, 2024. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.

The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Flospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

- 5. The statement includes results of the following entities:
  - i. Alembic City Limited (Subsidiary)
  - ii. Alembic Pharmaceuticals Limited (Associate)
- 6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose unaudited financial results reflect (before consolidated adjustments) total assets of Rs. 14,582.02 lakhs as at 30th September, 2024, total revenue of Rs. 928.40 lakhs and Rs. 1,817.02 lakhs, total net loss after tax of Rs. 41.54 lakhs and Rs. 93.84 lakhs and total comprehensive loss of Rs. 41.32 lakhs and Rs. 93.64 lakhs for the quarter ended 30th September, 2024 and the period ended on that day respectively and net cash inflow of Rs. 16.85 lakhs for the period from 1st April, 2024 to 30th September, 2024. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 4,370.78 lakhs and Rs. 8,210.47 lakhs and total comprehensive income of Rs. 4,407.88 lakhs and Rs. 8,152.25 lakhs for the quarter ended 30th September, 2024 and the period ended on that day respectively, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

VADODAR/

For C N K & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036

Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date: 8<sup>th</sup> November, 2024 UDIN: 24158289BKAQRC7611

# CNK & Associates LLP Chartered Accountants

Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Alembic Limited

- 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30<sup>th</sup> September, 2024 and year to date from 01<sup>st</sup> April, 2024 to 30<sup>th</sup> September, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### 4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Standalone Financial Statements for the year ended 31st March, 2024. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.

The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Rrasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

VADODARA

For C N K & Associates LLP Chartered Accountants Firm Registration No. 101961W/W-100036

Pellud ASSOC

Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date: 8<sup>th</sup> November, 2024 UDIN: 24158289BKAQRB8660